The most common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation and reflux — and they are dose-related, worst during dose escalation, and improve with time. Serious effects such as gallbladder disease and pancreatitis are uncommon. Feared effects such as thyroid cancer are not established in humans, although a personal or family history of medullary thyroid carcinoma or MEN2 is an absolute contraindication.
Common effects and rare ones
GLP-1 safety reporting tends to fall into two patterns: a common, manageable effect described as a crisis, or a rare effect described without its rarity. Across a large and growing safety record the class is generally well tolerated, with real but mostly manageable risks. → GLP-1 hub
Gastrointestinal effects
Gastrointestinal symptoms are the defining side effect of the class and the main reason people stop treatment. They come from the mechanism that makes the drugs work: slowed gastric emptying and central appetite suppression.
- Nausea — the most common. Usually mild-to-moderate, worst in the days after a dose increase, fading as the body adapts.
- Vomiting, diarrhea, constipation, reflux, burping, bloating — all reported and typically dose-related.
- Reduced appetite — expected and therapeutic, but profound appetite suppression can leave protein and overall nutrition too low.
Severity tracks the speed of dose escalation more than the drug itself, which is why severe or persistent symptoms are usually a reason to hold or step back the dose rather than continue through them. Grade A 🟢 that these effects are common, dose-related and usually improve.
Dehydration and the kidney
Severe or prolonged vomiting and diarrhea can cause dehydration, and dehydration — not a direct drug toxicity — is the usual route to acute kidney injury on these drugs. Risk concentrates in people with severe symptoms, older adults, and anyone taking diuretics, ACE inhibitors or ARBs, or NSAIDs. Days of vomiting warrant rehydration and early medical contact. Grade B 🟡
Gallbladder disease
GLP-1 therapy is associated with gallstones and gallbladder inflammation (cholecystitis). Part of this is attributable to the drug and a large part to rapid weight loss itself, a long-recognised gallstone risk regardless of its cause. New right-upper-abdominal pain, particularly after fatty meals and with nausea, warrants prompt evaluation. Grade B 🟡
Pancreatitis
Acute pancreatitis is a labelled caution, uncommon on these drugs but serious when it occurs: severe, persistent upper-abdominal pain radiating to the back, with vomiting, warrants stopping the drug and urgent assessment. A prior history is a reason for caution before starting. Grade B/C 🟠
EVIDENCE CARD · Pancreatitis and GLP-1 drugs
- WHAT'S SHOWN: Pancreatitis occurs and is listed as a caution; it is rare in trials and large post-marketing datasets.
- WHAT'S UNKNOWN: Whether GLP-1s raise risk above that of the population they treat, since obesity and diabetes independently raise pancreatitis and gallstone risk.
- OUR POSITION: A rare but real risk. History of pancreatitis warrants caution; new severe abdominal pain warrants stopping the drug. Grade C 🟠
Thyroid cancer and the rodent data
In rodent studies, GLP-1 receptor agonists caused thyroid C-cell tumors (medullary thyroid carcinoma, MTC — a cancer of the hormone-producing cells of the thyroid). That finding produced a boxed warning and an absolute contraindication in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2). It is not established as a human risk: rodent C-cells carry far more GLP-1 receptors than human ones, and human data have not confirmed a causal link.
EVIDENCE CARD · GLP-1 drugs and thyroid cancer
- WHAT'S SHOWN: Rodents developed thyroid C-cell (medullary) tumors, hence the boxed warning and the absolute contraindication in MTC or MEN2 history.
- WHAT'S UNKNOWN: Whether GLP-1 agonists cause any thyroid cancer in humans. Observational signals have been inconsistent and no causal link is established.
- OUR POSITION: Absolute contraindication in MTC/MEN2 or their family history. Otherwise the human risk is not established — caution based on animal data, not evidence of human harm. Grade C 🟠
Gastroparesis and delayed gastric emptying
These drugs slow gastric emptying by design, which is part of how they create fullness. Whether they also cause gastroparesis — clinically significant, persistent delayed emptying — is a separate question. The expected slowing is dose-related, eases over time and reverses when the drug is stopped; severe or persistent gastroparesis-like cases are reported and under study. People with pre-existing gastroparesis, including some with long-standing diabetes, warrant caution.
EVIDENCE CARD · Gastroparesis / delayed gastric emptying
- WHAT'S SHOWN: These drugs slow gastric emptying by design; some patients report severe, persistent symptoms consistent with gastroparesis.
- WHAT'S UNKNOWN: How often persistent gastroparesis occurs, and whether the drug causes it or unmasks it. Long-term reversibility data are limited.
- OUR POSITION: Some slowed emptying is expected; severe or persistent symptoms are taken seriously, caution applies with pre-existing gastroparesis, and perioperative holding guidance applies. Grade C 🟠
Surgery, anesthesia and aspiration
Because gastric emptying is slowed, the stomach may retain food longer than expected, and under anesthesia or deep sedation that raises the risk of aspiration — stomach contents entering the lungs. Anesthesia guidance now recommends holding GLP-1 medications before elective surgery and treating patients as potentially "full stomach." The same reasoning covers any sedated procedure, including endoscopy, colonoscopy and dental sedation, so the medication is disclosed to the teams involved, whose instructions govern when it is paused. Grade B 🟡
"Ozempic face" and skin changes
"Ozempic face" — a gaunt, hollowed or aged facial appearance — is not a drug toxicity. It is the visible result of losing facial fat during substantial weight loss, and equivalent weight loss from any cause produces it. Faster, larger loss makes it more noticeable, particularly in older adults with less skin elasticity. Grade A 🟢 (that it reflects fat loss, not toxicity).
Hair loss (telogen effluvium)
Hair thinning during GLP-1 treatment is, in the great majority of cases, telogen effluvium — the temporary, diffuse shedding that follows any rapid weight loss, major stressor or reduced nutrient intake. It is not scarring and not permanent, and typically recovers as weight stabilizes, with adequate protein, iron and nutrition supporting regrowth. Grade B 🟡 → GLP-1 & Muscle Loss (protein and body composition).
Muscle and lean mass
Any substantial weight loss — from diet, surgery or GLP-1 drugs — reduces fat-free mass alongside fat. A falling DXA lean-mass number is routinely read as proof the drug destroyed muscle, which it is not: lean mass includes water and organ tissue, most of the loss is fat, and protein with resistance training meaningfully protects muscle and function. → GLP-1 & Muscle Loss. Grade C 🟠
Mood and mental health
Regulators reviewed reports of suicidal thoughts and, to date, large analyses have not established that GLP-1 drugs cause depression or suicidality. Many patients instead report improved mood and reduced food preoccupation. A history of depression or disordered eating, or any new mood change, warrants monitoring, and new suicidal thoughts warrant urgent attention regardless of cause. Grade C 🟠 (no established causal harm; monitor individually). → Food Noise
Injection-site and other minor effects
Injection-site redness or itching, fatigue, dizziness and headache are reported and usually minor; fatigue often tracks reduced intake early on. Grade B 🟡
What the evidence says: GLP-1 side effects
- What we know: Gastrointestinal effects are common, dose-related and usually improve; gallbladder disease and pancreatitis are uncommon; delayed gastric emptying matters before surgery; the MTC/MEN2 contraindication is firm.
- What we think: Most feared effects, including thyroid cancer and depression, reflect caution or rare events rather than demonstrated common harm; "Ozempic face" and hair loss are weight-loss phenomena rather than toxicities.
- What we don't know: True rates of persistent gastroparesis; decade-plus safety; long-term muscle and bone outcomes.
Which of these risks matters for a particular person depends on their history, medications and dose, which an individual assessment at the practice establishes.
Questions patients ask
What are the most common side effects?
Gastrointestinal — nausea, vomiting, diarrhea, constipation, reflux — mostly during dose increases, usually improving with time and slow titration. Grade A 🟢
Do GLP-1s cause thyroid cancer?
Rodent studies showed medullary (C-cell) thyroid tumors, which is why there is a boxed warning and a contraindication in MTC or MEN2. It is not established as a human risk otherwise. Grade C 🟠
Does the drug have to be stopped before surgery?
Current guidance generally recommends holding GLP-1s before surgery because delayed stomach emptying raises aspiration risk; the anesthesia team's instructions govern the timing. Grade B 🟡
Is "Ozempic face" a drug side effect?
No — it is facial fat loss from weight loss itself, not a toxicity. Any equivalent weight loss would do the same. Grade A 🟢
Does hair loss happen, and is it permanent?
Some people shed hair temporarily (telogen effluvium) with rapid weight loss; it usually recovers with weight stabilization and adequate protein. It is not permanent. Grade B 🟡
Can these drugs damage the pancreas?
Pancreatitis is a rare but real risk, and a prior history warrants caution. Severe persistent upper-abdominal pain means stopping the drug and seeking care. Grade C 🟠
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: FDA prescribing information for semaglutide and tirzepatide (boxed warning, contraindications); STEP and SURMOUNT programs; anesthesiology society guidance on perioperative GLP-1 management. Educational; not individualized medical advice.
